175 related articles for article (PubMed ID: 35835707)
1. Current status and future perspective on the management of metastatic castration-sensitive prostate cancer.
Blas L; Shiota M; Eto M
Cancer Treat Res Commun; 2022; 32():100606. PubMed ID: 35835707
[TBL] [Abstract][Full Text] [Related]
2. Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis.
Ciccarese C; Iacovelli R; Sternberg CN; Gillessen S; Tortora G; Fizazi K
Eur J Cancer; 2022 Sep; 173():276-284. PubMed ID: 35964470
[TBL] [Abstract][Full Text] [Related]
3. Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer.
Grisay G; Lavaud P; Fizazi K
Curr Oncol Rep; 2024 May; 26(5):488-495. PubMed ID: 38592590
[TBL] [Abstract][Full Text] [Related]
4. A Real-World Evidence Study Using Alberta-Population-Based Data to Describe Treatment Patterns for Metastatic Castration-Sensitive Prostate Cancer Patients (AWARENESS).
Karim S; Lowther J; Gyulay G; O'Sullivan D; Wallis CJD; Yip SM; Brenner DR; Boyne DJ; Cheung WY
Curr Oncol; 2023 Sep; 30(9):8149-8158. PubMed ID: 37754506
[TBL] [Abstract][Full Text] [Related]
5. Combination Androgen Receptor Inhibition and Docetaxel in Metastatic Castration-sensitive Prostate Cancer: The Next Step in First-line Treatment?
Adashek JJ; Reed JP; Tandon A; Freedland SJ; Posadas E; Bhowmick N; Chung LW; Freeman M; Figlin RA; Gong J
Clin Genitourin Cancer; 2020 Dec; 18(6):425-428. PubMed ID: 32631766
[TBL] [Abstract][Full Text] [Related]
6. SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer.
Swami U; Graf RP; Nussenzveig RH; Fisher V; Tukachinsky H; Schrock AB; Li G; Ross JS; Sayegh N; Tripathi N; Mathew Thomas V; Oxnard GR; Antonarakis ES; Agarwal N
Clin Cancer Res; 2022 Nov; 28(22):4917-4925. PubMed ID: 36088616
[TBL] [Abstract][Full Text] [Related]
7. Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy.
Narita S; Kimura T; Hatakeyama S; Hata K; Yanagisawa T; Maita S; Chiba S; Sato H; Kashima S; Koizumi A; Yamamoto R; Takayama K; Okane K; Ishida T; Horikawa Y; Kumazawa T; Shimoda J; Suzuki T; Ohyama C; Egawa S; Nomura K; Habuchi T
World J Urol; 2022 May; 40(5):1135-1141. PubMed ID: 35218371
[TBL] [Abstract][Full Text] [Related]
8. Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis.
Buonerba C; Ferro M; Dolce P; Crocetto F; Verde A; Lucarelli G; Scafuri L; Facchini S; Vaia A; Marinelli A; Terracciano D; Montella L; Longo N; Imbimbo C; Mirone V; Di Lorenzo G; De Placido S; Sonpavde G
Crit Rev Oncol Hematol; 2020 Jul; 151():102992. PubMed ID: 32474391
[TBL] [Abstract][Full Text] [Related]
9. Real-World Treatment Trends Among Patients with Metastatic Castration-Sensitive Prostate Cancer: Results from an International Study.
Barata PC; Leith A; Ribbands A; Montgomery R; Last M; Arondekar B; Ivanova J; Niyazov A
Oncologist; 2023 Sep; 28(9):780-789. PubMed ID: 37014080
[TBL] [Abstract][Full Text] [Related]
10. [Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer].
Hammerer P; Manka L
Urologe A; 2019 Oct; 58(10):1185-1197. PubMed ID: 31127324
[TBL] [Abstract][Full Text] [Related]
11. Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)-A Potential New Standard of Care.
Mittal A; Sridhar SS; Ong M; Jiang DM
Curr Oncol; 2023 Apr; 30(4):4365-4378. PubMed ID: 37185445
[TBL] [Abstract][Full Text] [Related]
12. Emergence of triplet therapy for metastatic castration-sensitive prostate cancer: An updated systematic review and network meta-analysis.
Sathianathen NJ; Pan HYC; Lawrentschuk N; Siva S; Azad AA; Tran B; Bolton D; Murphy DG
Urol Oncol; 2023 May; 41(5):233-239. PubMed ID: 36411180
[TBL] [Abstract][Full Text] [Related]
13. Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate Cancer.
Wallis CJD; Malone S; Cagiannos I; Morgan SC; Hamilton RJ; Basappa NS; Ferrario C; Gotto GT; Fernandes R; Niazi T; Noonan KL; Saad F; Hotte SJ; Hew H; Chan KFY; Wyllie LP; Shayegan B
JNCI Cancer Spectr; 2021 Dec; 5(6):. PubMed ID: 34926988
[TBL] [Abstract][Full Text] [Related]
14. First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis.
Riaz IB; Naqvi SAA; He H; Asghar N; Siddiqi R; Liu H; Singh P; Childs DS; Ravi P; Hussain SA; Murad MH; Boorjian SA; Sweeney C; Van Allen EM; Bryce AH
JAMA Oncol; 2023 May; 9(5):635-645. PubMed ID: 36862387
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Upfront Docetaxel With Androgen Deprivation Therapy for Castration-Sensitive Metastatic Prostate Cancer Among Minority Patients.
Pathak S; Thekkekara R; Yadav U; Ahmed AT; Yim B; Lad TE; Mullane M; Batra KK; Aronow WS; Psutka SP
Am J Ther; 2020 May; 28(4):e380-e387. PubMed ID: 32384317
[TBL] [Abstract][Full Text] [Related]
16. Treating De Novo Metastatic Castration-Sensitive Prostate Cancer With Visceral Metastases: An Evolving Issue.
Roviello G; Petrioli R; Villari D; D'Angelo A
Clin Genitourin Cancer; 2021 Feb; 19(1):83-86. PubMed ID: 32665085
[TBL] [Abstract][Full Text] [Related]
17. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
18. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Fizazi K; Foulon S; Carles J; Roubaud G; McDermott R; Fléchon A; Tombal B; Supiot S; Berthold D; Ronchin P; Kacso G; Gravis G; Calabro F; Berdah JF; Hasbini A; Silva M; Thiery-Vuillemin A; Latorzeff I; Mourey L; Laguerre B; Abadie-Lacourtoisie S; Martin E; El Kouri C; Escande A; Rosello A; Magne N; Schlurmann F; Priou F; Chand-Fouche ME; Freixa SV; Jamaluddin M; Rieger I; Bossi A;
Lancet; 2022 Apr; 399(10336):1695-1707. PubMed ID: 35405085
[TBL] [Abstract][Full Text] [Related]
19. First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings.
Ferro M; Lucarelli G; Crocetto F; Dolce P; Verde A; La Civita E; Zappavigna S; de Cobelli O; Di Lorenzo G; Facchini BA; Scafuri L; Onofrio L; Porreca A; Busetto GM; Sonpavde G; Caraglia M; Klain M; Terracciano D; De Placido S; Buonerba C
Crit Rev Oncol Hematol; 2021 Jan; 157():103198. PubMed ID: 33316417
[TBL] [Abstract][Full Text] [Related]
20. Treatment Intensification Patterns and Utilization in Patients with Metastatic Castration-Sensitive Prostate Cancer.
Heath EI; Dyson GE; Cackowski FC; Hafron J; Powell I
Clin Genitourin Cancer; 2022 Dec; 20(6):524-532. PubMed ID: 35864053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
